SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides (SOLAR)
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
Please refer to this study by its ClinicalTrials.gov identifier: NCT03713320
miRagen Therapeutics, Inc.
6200 Lookout Road
Boulder, CO 80301
Study Director: Diana M. Escolar, MD, FAAN
Overall Recruitment Status
Active, not recruiting
The SOLAR study is ongoing. Patients participating in the study at this time continue to receive treatment and are being evaluated for potential benefits and side effects. The study is not currently enrolling new patients until the results of study data from a mid-study time point are reviewed. This mid-study review is expected to occur in the second half of 2020. The mid-study data review will provide early insight into the effect of cobomarsen in patients with CTCL and will inform future enrollment into the SOLAR study.
United States, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210